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Background and purpose: Drug responses vary markedly from patient to patient in atrioventricular nodal
reentrant tachycardia (AVNRT), themost common formof paroxysmal regular supraventricular tachycar-
dia inadults.However, clinical andelectrophysiological (EP) characteristicsofpatientswithAVNRTwhose
tachycardia attacks could not be adequately controlled by antiarrhythmic agents have not been studied
in a large patient cohort. We aimed to deﬁne the clinical and EP features of patients with drug-refractory
AVNRT.
Methods and results: A total of 266 consecutive patients with AVNRT undergoing catheter ablation after
a period of medical treatment were analyzed: 144 patients with drug-refractory AVNRT (Group 1) and
122 patients with drug-responsive AVNRT (Group 2). Age was signiﬁcantly higher (p=0.027) and the
presence of hypertension (p=0.030), diabetes mellitus (p=0.047), and valvular heart diseases (p=0.008)
was more frequent in Group 1 compared to Group 2. Among the EP features, atrial-His jump (81% vs 69%,
p=0.028) and atrial vulnerability (26% vs 14%, p=0.018) were signiﬁcantly higher, echo zone was signif-
icantly more long-lasting (44±24ms vs 38±22ms, p=0.018), and tachycardia cycle length (TCL) was
signiﬁcantly longer (348±41msvs 329±38ms,p=0.000) inGroup1 than inGroup2.Multivariate analy-
sis showed that hypertension (p=0.036), valvular heart disease (p=0.014), atrial vulnerability (p=0.037),
TCL (p=0.003), and wide echo zone (p=0.028) were independent predictors for drug-refractory AVNRT.
Conclusion: In the presence of hypertension, valvular heart disease, atrial vulnerability, long-lasting echo
AVNR
4 Japzone, and relatively slow
© 201
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Atrioventricular nodal reentrant tachycardia (AVNRT) is the
ost common form of paroxysmal regular supraventricular
achycardia (SVT) in adults, accounting for 60% of the cases [1].
adiofrequency (RF) catheter ablation has become the ﬁrst-line
reatment approach with high acute success and low complication
ates [2–4]. On the other hand, antiarrhythmic therapy still plays
role in the majority of patients in the acute and long-term
anagement of SVT [5]. However, drug responses vary markedly
rom patient to patient in AVNRT, satisfactory control being
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ax: +90 274 2652016.
E-mail addresses: dramasyali@yahoo.com,
asri.amasyali.ba@gmail.com (B. Amasyali).
914-5087/$ – see front matter © 2014 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2014.01.009T, medical treatment is less likely to prevent the tachycardia episodes.
anese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
achieved in only 60% of the cases [6–8]. Even the so-called tailored
therapy regimens as directed by electrophysiological (EP) studies
before initiation of antiarrhythmic treatment can barely reach
success rates of 70–80% [9–12]. Thus, drug-refractory AVNRT is a
considerable health problem hampering the individual’s quality of
life [13]. Data are not yet available about the clinical characteristics
and EP features of patients with drug-refractory AVNRT. The aim
of this study was to compare clinical and EP characteristics as well
as catheter ablation results in patients with drug-responsive and
drug-refractory AVNRT.
MethodsPatients
The subjects of this study consist of 266 consecutive patients
treated with RF catheter ablation for symptomatic AVNRT. All
vier Ltd. All rights reserved.
f Card
p
6
m
f
P
A
i
t
a
o
t
w
A
b
c
d
i
i
a
E
s
d
l
a
i
b
(
5
ﬁ
t
A
t
m
i
r
a
u
l
t
l
[
(
t
M
a
6
a
a
w
o
w
o
F
h
l
t
aB. Amasyali et al. / Journal o
atients had a history of paroxysmal palpitations ranging from
months to 26 years. The frequency of tachycardia attacks docu-
ented on electrocardiographic (ECG) or Holter recordings varied
rom at least once in a month to three to four attacks in a year.
atients who experienced at least one documented episode of
VNRT in the previous 3 months before ablation despite max-
mum tolerable doses of antiarrhythmic agents were taken as
he study group (n=144; Group 1). Patients who did not have
ny palpitations on medications in the previous 6 months but
pted to discontinue medication and undergo catheter abla-
ion served as the control group (n=122; Group 2). Patients
ith poor drug compliance or different EP diagnoses other than
VNRT were excluded from the study. The study was approved
y the institutional ethical committee and informed written
onsent was obtained from each patient for the ablation proce-
ure.
All the patients underwent 12-lead surface ECG, X-ray exam-
nation, echocardiography, and blood chemistry measurements
ncluding thyroid testing and, when clinically indicated, stress test
nd 24-h Holter ECG recording.
P study and RF catheter ablation
EP study and catheter ablation were performed in a single
ession in all patients in the fasting, unsedated state and after
iscontinuation of all antiarrhythmic drugs for at least ﬁve half-
ives. The standard protocol consisted of decremental high right
trial (A1A1) pacing, usually starting from 600ms and decreasing
n steps of 10ms until the atrioventricular (AV) node Wencke-
ach cycle length was reached, and single atrial extrastimulus
A1A2) testing at three different drive train cycle lengths (600,
00, and 430ms) to induce tachycardia. During pacing with the
rst drive train, the A1–A2 interval was shortened by 10ms until
he AV node effective refractory period (ERP) had been reached.
jump of the atrial-His bundle (AH) interval was deﬁned as
he difference between any consecutive AH intervals equal to or
ore than 50ms during programmed or incremental atrial pac-
ng. Programmed electrical stimulation was performed from the
ight ventricle to investigate the ventriculoatrial (VA) conduction
t baseline. All basic EP data were collected with the patients
nsedated and before infusion of any pharmacological stimu-
ants except for tachycardia parameters in those patients whose
achycardia could be induced only under pharmacologic stimu-
ation. AVNRT was diagnosed according to the standard criteria
1,14].
Slow pathway ablation was done with the integrated
electrogram-guided anatomic) approach, using 7 Fr quadripolar
ip-deﬂectable catheters with 4-mm tip electrodes (Marinr MC,
edtronic Co., Minneapolis, MN, USA). Fifty watts of energy with
temperature limit of 65 ◦C was applied at successful sites for
0–90 s. RF delivery was terminated if junctional rhythm did not
ppear in the ﬁrst 15 s and the catheter was moved to the mid-
nd anterior septum to repeat the procedure until the endpoints
ere reached. The endpoints of ablation were the demonstration
f either a slow pathway block or a slow pathway modiﬁcation
ith no more than one single echo beat along with noninducibility
f AVNRT.
ollow-up after RF catheter ablationAll the patients were discharged 2 days postoperatively. After
ospital discharge, all patientswere scheduled for a visit 4–6weeks
ater and every 3 months thereafter in the ﬁrst year. If palpita-
ions recurred, the patients were asked to obtain an ECG as soon
s possible and contact our center.iology 64 (2014) 302–307 303
Statistical analysis
Continuous variables were expressed as mean± standard devi-
ation. Groups were compared by means of chi-square analysis or
Fischer’s exact test when needed for discrete variables and with
unpaired Student’s t test for continuous variables.
Logistic regression analysis was used to examine and determine
the predictors for drug-refractory AVNRT. The following variables
were put into the model: age, gender, duration of symptoms, pres-
ence of hypertension, diabetes mellitus, valvular heart disease,
coronary artery disease, left ventricular hypertrophy, left ventricu-
lar ejection fraction, andEPparameters;AVnodeWenckebachcycle
length, AV node anterograde ERP, presence of AH jumps, multiple
AH jumps, echo zone duration, atrial vulnerability, the frequency of
using pharmacologic stimulation to induce AVNRT, type of AVNRT,
and tachycardia cycle length (TCL). Variables with p<0.20 in uni-
variate analyses were included into the multivariate analyses. In
multivariate analysis, backward LR elimination was used to com-
pare and build the appropriate model. Likelihood ratio values were
considered for the reduction of the model.
Statistical comparisons were performed using the statistical
software package SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Calculated
p-values of less than 0.05 were considered signiﬁcant.
Results
The study group (Group 1) included 144 patients (79 women
and 65 men; mean age 43±15 years, range 17–84 years) and the
control group (Group 2) consisted of 122 patients (64 women and
58 men; mean age 39±14 years, range 20–78 years).
Clinical characteristics
Clinical characteristics of groups are shown in detail in
Table 1. Age was signiﬁcantly higher (p=0.027) and hypertension
(p=0.030), diabetesmellitus (p=0.047), andvalvular heart diseases
(p=0.008) were more frequent in Group 1 as compared to Group
2. There was no difference between the study and control groups
regarding the antiarrhythmic therapy regimen (Table 1).
Electrophysiological characteristics
The presence of discontinuous AV conduction was more fre-
quent (p=0.028) and the echo zone was seen to last slightly but
signiﬁcantly longer (44±24ms vs 38±22ms, p=0.018) in Group
1 than in Group 2. The TCL was signiﬁcantly longer in Group 1
(p<0.001). The lower rate of AVNRT was due to the longer AH
intervals (p=0.019) in this group. The His-ventricle and VA inter-
vals during tachycardia did not differ between the groups (p>0.05
for both). The need for pharmacological stimulation to induce
tachycardia did not differ between the groups (p>0.05). EP charac-
teristics of patients are shown in detail in Table 2.
Sustained atrial ﬁbrillation (AF) lasting for more than 30 s was
induced (atrial vulnerability) in 54 of 266 patients during EP study.
Thirty-seven of these cases were in Group 1 (26%) and 17 were
in Group 2 (14%) (p=0.018). AF was converted spontaneously into
sinus rhythm in the ﬁrst 15min in 47 patients (87%) and was elec-
trically converted in 7 patients (13%). AF was induced through the
degeneration of AVNRT in eight patients (15%); of these, threewere
in Group 1 and 5 in Group 2, the difference between the groups
not being statistically signiﬁcant (p>0.050). AF was induced dur-
ing programmed atrial stimulation or burst pacing in the rest of the
46 patients (85%). AF occurring during catheter manipulation was
not taken into consideration.
A comparison of the EP variables of the groups with regard to
the antiarrhythmic drugs failed to reveal any additional statistically
signiﬁcant difference between the groups. Among patients taking
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Table 1
Baseline clinical characteristics of groups.
Group 1 (n=144) Group 2 (n=122) p
Age (years), mean± SD (range) 43±15 (17–84) 39±14 (20–78) 0.027
Male/female 65/79 58/64 ns
Systemic hypertension, n (%) 41 (29) 21 (17) 0.030
Diabetes mellitus, n (%) 31 (22) 15 (12) 0.047
Structural heart disease
Valvular heart disease, n (%) 30 (21) 11 (9) 0.008
Coronary artery disease, n (%) 21 (15) 17 (14) ns
Left ventricular hypertrophy, n (%) 23 (16) 10 (8) 0.055
LVEF<50%, n (%) 12 (8) 6 (5) ns
Duration of symptoms (years) 9.0±6.3 7.7±6.0 ns
Frequency of tachycardia (attacks/6-month)
before antiarrhythmics 3.9±1.4 3.7±1.3 ns
after antiarrhythmics 2.8±0.9 0 0.000
Exercise provokable tachycardia, n (%) 59 (41) 60 (49) ns
Medication
Beta-blocker, n (%) 57 (40) 49 (40) ns
Calcium-channel blockers, n (%) 52 (36) 50 (41) ns
Other antiarrhythmics,a n (%) 16 (11) 7 (6) ns
Combined antiarrhythmics, n (%) 19 (13) 16 (13) ns
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nVEF, left ventricular ejection fraction; ns, not signiﬁcant.
a Class-I or Class-III antiarrhythmic agents.
eta-blockers or calcium-channel blockers, discontinuous AV con-
uction (83% in Group 1 vs 67% in Group 2, p=0.008), echo zone
idth (47±21ms in Group 1 vs 37±22ms in Group 2, p=0.002),
CL (349±44ms in Group 1 vs 330±41ms in Group 2, p=0.002),
nd atrial vulnerability (28% inGroup1 vs 11% inGroup2, p=0.002)
ere seen to differ signiﬁcantly between the groups. However,
hen the patient subgroups taking antiarrhythmic agents other
han beta-blockers or calcium-channel blockers were analyzed, it
as observed that only TCL (345±33ms vs 323±24ms, p=0.007)
iffered signiﬁcantly while discontinuous AV conduction (74% vs
8%, p>0.05), atrial vulnerability (17% vs 26%, p>0.05), and the
cho zone (37±29ms vs 39±20ms, p>0.05) did not show any
igniﬁcant difference between Group 1 and Group 2, respectively.
F catheter ablation and follow-up after ablation
The results of RF ablation are shown in Table 3. AVNRT was
liminated with right endocardial approach in all cases except one,
hich was successfully ablated from the mitral septum. No differ-
nce was noted between the groups with respect to the successful
blation site in Koch’s triangle.
Transient second-degree Mobitz type I AV block lasting less
han 30 s was seen in two patients (1%) in Group 1 and one
able 2
lectrophysiological characteristics of groups.
Group 1 (n=144)
AV node WCL (ms) 326±30
AV node antegrade ERP (ms) 230±20
Maximum AH interval (ms) 319±35
AH jump, n (%) 116 (81)
Multiple AH jumps, n (%) 22 (15)
1:1 VAC 129 (90)
Echo zone (ms) mean± SD 44±24
Atrial vulnerability, n (%) 37 (26)
Type of AVNRT
Typical, n (%) 135 (94)
Atypical, n (%) 9 (6)
Tachycardia parameters
TCL (ms) 348±41
AH interval 228±50
hRA-VA interval (ms) 74±27
Atropine, n (%) 32 (22)
V, atrioventricular;WCL,Wenckebach cycle length; ERP, effective refractory period; AH,
odal reentrant tachycardia; TCL, tachycardia cycle length; hRA-VA, ventriculoatrial interpatient (1%) in Group 2 (p>0.050). Permanent PR prolongation
was observed in three patients (2%) in Group 1 and one patient
(1%) in Group 2 (p>0.050). One patient in Group 1, in whom AV
conduction was intact during and after the ablation procedure,
developed symptomatic intermittent third-degree AV block 3
months after the procedure and received a permanent pacemaker.
There were no differences between the groups with respect
to the number of RF pulses (5.0±2.8 in Group 1 and 4.9±2.5 in
Group2;p>0.050), procedureduration (42±18min inGroup1and
40±16min in Group 2; p>0.050), and total ﬂuoroscopy duration
(13±6min in Group 1 and 12±6min in Group 2; p>0.050).
During follow-up, recurrence of AVNRT was observed in three
patients and all of them were treated successfully with a second
session. The recurrence rate of AVNRT did not differ between the
groups (p>0.05, Table 3).
Predictors for drug-refractory AVNRT
The factors associated with drug-refractory AVNRT are shown
in Table 4. In univariate analysis, signiﬁcant predictors for drug-
refractory AVNRT were age (p=0.028), hypertension (p=0.032),
diabetes mellitus (p=0.049), valvular heart disease (p=0.010),
atrial vulnerability (p=0.019), discontinuous AV conduction
Group 2 (n=122) p
323±33 ns
233±23 ns
318±37 ns
84 (69) 0.028
15 (12) ns
103 (84) ns
38±22 0.018
17 (14) 0.018
113 (93) ns
9 (7) ns
329±38 0.000
214±50 0.019
71±31 ns
26 (21) ns
atrial-His bundle; 1:1 VAC, 1:1 ventriculoatrial conduction; AVNRT, atrioventricular
val at the high right atrium; ns, not signiﬁcant.
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Table 3
Results of radiofrequency catheter ablation.
Group 1 (n=144) Group 2 (n=122) p
Success rate, n (%) 144 (100) 122 (100) ns
Successful ablation site
Midseptal, n (%) 81 (56) 65 (53) ns
Posteroseptal, n (%) 62 (43) 57 (47) ns
Left midseptal, n (%) 1 (1) 0 ns
PR prolongation, n (%) 3 (2) 1 (1) ns
Transient AVB, n (%) 2 (1) 1 (1) ns
Permanent complete AVB, n (%) 1 (1) 0 ns
Residual dual pathway, n (%) 28 (19) 26 (21) ns
Residual single echo beat, n (%) 18 (13) 14 (12) ns
Recurrence of AVNRT, n (%) 1 (1) 2 (2) ns
Follow-up duration (months) 22±10 23±11 ns
AVNRT, atrioventricular nodal reentrant tachycardia; AVB, high-grade atrioventricular block; ns, not signiﬁcant.
Table 4
Univariate and multivariate predictors for drug-refractory AVNRT.
RR 95% CI p
Univariate predictors
Age 1.019 1.002–1.036 0.028
Hypertension 1.914 1.058–3.465 0.032
Diabetes mellitus 1.957 1.001–3.827 0.049
Valvular heart disease 2.656 1.269–5.558 0.010
Atrial vulnerability 2.136 1.133–4.027 0.019
Discontinuous AV conduction 1.874 1.067–3.291 0.029
TCL 1.012 1.006–1.019 0.000
Echo zone 1.013 1.002–1.024 0.019
Multivariate predictors
Hypertension 1.975 1.045–3.733 0.036
Valvular heart disease 2.628 1.215–5.688 0.014
Atrial vulnerability 2.039 1.044–3.982 0.037
Echo zone 1.013 1.001–1.025 0.028
TCL 1.010 1.003–1.017 0.003
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tCL, tachycardia cycle length; AV, atrioventricular; RR, relative risk; CI, conﬁdence
p=0.029), TCL (p=0.000), and wide echo zone (p=0.019). How-
ver, using the multivariate analysis, two clinical and three EP
eatures emerged as independent predictors for drug-refractory
VNRT. Clinical features were hypertension (p=0.036) and valvu-
ar heart disease (p=0.014). Independent EP predictors were atrial
ulnerability (p=0.037), TCL (p=0.003), and echo zone (p=0.028)
Table 4).
iscussion
This study analyzes the clinical and EP characteristics of patients
ith AVNRT whose tachycardia episodes could not be controlled
ith the most common antiarrhythmic agents. The results of this
tudy demonstrate that patients with drug-refractory AVNRT tend
o be older, and more commonly suffer from valvular heart dis-
ase, diabetes mellitus, and hypertension when compared to those
atients whose tachycardia is well controlled medically. Among
he EP data, AH jumps in the AV conduction curve and atrial vul-
erability were more frequent, echo zones were more long-lasting,
nd TCL were slightly but signiﬁcantly longer in patients with
rug-refractory AVNRT. Hypertension, valvular heart disease, atrial
ulnerability, lower rates of AVNRT, and wide echo zones were
dentiﬁed as independent predictors for drug-refractory AVNRT.
Inour study,drug therapy is seen tobe lessefﬁcacious inpatients
ith relatively slower AVNRT. In a previous study, Ballo et al.
15] have reported that verapamil is less effective in patients with
aroxysmal SVT with higher rates and suggested that the rate of
achycardia may have a deﬁnitive role in the acute treatment of
aroxysmal SVT. Although these results are not compatible with
urs, there are two important differences in the studydesigns. First,
heir study involved patients with paroxysmal SVT; the number ofal.
patients diagnosed with AVNRT is not known. AVNRT cases have
been evaluated along with tachycardia types having entirely dif-
ferent EP properties such as atrial tachycardia or atrioventricular
reentrant tachycardia. It iswell known that the rate of AV reentrant
tachycardia is usually higher than the rate of AVNRT and different
subtypes of paroxysmal SVT may show unequal responsiveness to
antiarrhythmic agents [16]. Second, Ballo et al. studied the activ-
ity of verapamil in the conversion of ongoing SVT to sinus rhythm.
Interruption of an ongoing reentry and prevention of initiation of
a reentry involve different electropharmacological responses. The
former involves interruption of a reentry cycle through alteration
of ERP, while the latter targets elimination of triggers and/or pre-
vention of activation of the reentry cycle by these triggers. As is
known, the most common triggers for an episode of AVNRT are
atrial or, sometimes, ventricular ectopic beats. Inability to suppress
these ectopic beats effectively with current antiarrhythmic agents
may be the fact behind high failure rates of medical therapy.
Consistent with our ﬁndings, Wu et al. studied the effects of
propranolol on inducibility of AVNRT during EP study and found
that propranolol could not prevent inducibility of AVNRT in cases
with lower tachycardia rates [17]. Additionally, it has been sug-
gested that apredominantparasympatheticmodulationof the right
atrial input to the AV node with a consequent conduction delay
might have pro-arrhythmic effects in patients with AVNRT [18].
An increase in refractoriness in one pathway could be offset by an
increase in the conduction time in the opposing pathway of the
reentrant circuit.Critical AH interval is of fundamental importance in the induc-
tion of AVNRT [19]. Another important factor in the inducibility
of AVNRT is the echo zone, which is indirectly related to the crit-
ical AH interval. The echo zone is deﬁned as the zone in which
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trial extrastimuli induce atrial echo beats with or without AVNRT
17,20]. The outer and inner limits of this zone are the longest and
hortest A1–A2 stimuli followedby an atrial echo beat, respectively.
eentry is likely to be induced with extrastimuli slightly shorter
han the outer limit of the echo zone and noninducible below the
nner limit of the echo zone. Antiarrhythmic drugs have different
P effects [6,11,21]. It has been reported that Class Ic antiarrhyth-
ic agents are more effective in the presence of wide echo zones
ndClass III agents in short-lasting ones [9,22,23]. However, among
ur patients using Class I or Class III agents, the width of the echo
one did not differ signiﬁcantly between the drug-responsive and
rug-refractory AVNRT groups, although it was slightly wider in
he drug-refractory group. This could possibly result from the rel-
tively small number of cases, as most patients undergo ablation
t this stage. Besides, these drugs are known to decrease excitabil-
ty, suppress spontaneous automaticity and triggered activity, and
ncrease refractoriness in the atrial or ventricular myocardium as
ell as in the AV node, speciﬁcally on the retrograde fast pathway,
ll of which are important in both the initiation and continuation
f the AVNRT [6]. Thus, when compared to drugs affecting pre-
ominantly the antegrade slow pathway, width of the echo zone
ay not be as important in controlling the tachycardia episodes
ith Class I or Class III drugs. On the other hand, there are no clear
ata about the efﬁcacy of Class II or Class IV drugs in the preven-
ion of AVNRT episodes with respect to the width of the echo zone.
n our study, the echo zones were wider in drug-refractory AVNRT
atients taking beta-blockers or calcium-channel blockers. The fact
hat the broader the echo zone, the more persistent the critical AH
elay, which renders the AVNRT easier to trigger in daily life, could
artly explain why drugs affecting predominantly the antegrade
low pathway, namely Class II or Class IV, are less effective in the
revention of AVNRT episodes in patients with wider echo zones.
Premature depolarizations are known to be important for the
nitiation of AVNRT, while sympathetic predominance helps sus-
ain the tachycardia, as shown byNigro et al. [24]. Higher incidence
f structural heart disease and hypertension in Group 1 may con-
ribute to the development of drug-refractory AVNRT attacks via
oth increased premature beats and sympathetic predominance
n these patients. It has been suggested that reduced reﬂex vagal
ctivity may contribute to the development of sustained AVNRT in
atients with dual AV nodal physiology [25].
The incidenceof paroxysmalAF is higher inpatientswithAVNRT
han in the healthy population and is around 15–20% [26]. The
resence of atrial vulnerability seems to be an important predic-
or in patients with coexisting AVNRT and AF. We have previously
eported that in patients with AF and AVNRT attacks, the AF recur-
ence rates were signiﬁcantly higher after successful ablation of
VNRT in those with atrial vulnerability [27]. The atrial refractory
eriod, the dispersion of refractoriness, and intra- and inter-atrial
onduction delays are considered determinants of atrial vulnera-
ility [28]. In our study, atrial vulnerability was more frequent in
atients with drug-refractory AVNRT. It is not possible to explain
he reasons for this ﬁnding, as the study design did not involve
earching for the causes of atrial vulnerability. It can be speculated
hat the electromechanical remodeling leading to atrial vulnera-
ility might also enhance triggering and sustaining of AVNRT and
amper its response to drugs. Whether the autonomic or mechan-
cal effects have a determining role in this process needs to be
lariﬁed by future studies.
Otomo and coworkers have shown that concealed atriohisian
racts exist in approximately one-third of patients with typical
VNRT, most of which are resistant to adenosine and possibly
ondecremental, and they suggest that the lower turnaround
f the reentrant circuit might be located within the His bun-
le in these patients [29]. Moreover, Akhtar et al. reported that
uch a retrograde fast pathway did not exhibit VA prolongationiology 64 (2014) 302–307
after administration of verapamil [30]. The mechanism respon-
sible for such “Kent bundle-like” behavior of the retrograde fast
pathway was considered to be retrograde bypass of the AV node
[31,32]. Given the fact that beta-blockers or dihydropyridine group
of calcium-channel blockers exerts their effects through reentry
circuits with decremental behavior, the presence of concealed atri-
ohisian tracts capable of nondecremental conduction or retrograde
fast pathways with “Kent bundle-like” behavior could be respon-
sible for drug-refractory AVNRT in some cases. The possible role
of the unusual concepts of concealed atriohisian pathways, lower
turnaround of the reentrant circuit inside the His bundle, or Kent
bundle-like behavior of the retrograde fast pathway in the mecha-
nism of drug-refractory AVNRT remains to be elucidated in future
studies.
Study limitations
There is no standard objective deﬁnition for drug-refractory
AVNRT in the literature. Some physicians might consider medical
treatment successful in case of a single AVNRT attack in 6 months.
We preferred not to deﬁne drug-refractory AVNRT with two or
more attacks in 6 months so as not to leave a gray zone. Besides, in
our study, the average number of attacks in the last 6 months was
2.8±0.9. Thus, an attack frequency in this range can be considered
appropriate to deﬁne failure of medical treatment.
In our study, approximately 80% of the patients in each group
were taking beta-blockers or calcium-channel blockers, which are
mentioned in current guidelines among Class I indications in the
prevention of AVNRT recurrences. Patients taking beta-blockers or
calcium-channel blockers could have been asymptomatic if they
had used more potent Class I or Class III antiarrhythmic drugs or
combined therapy, and vice versa. However, the purpose of our
studywas not to determine the stepwise efﬁcacy of antiarrhythmic
drugs, either single or combined, on AVNRT episodes.
Conclusion
The present study shows that hypertension, valvular heart
disease, atrial vulnerability, wide echo zone, and relatively slow
AVNRT are independent predictors for AVNRT that is likely unre-
sponsive to more commonly prescribed antiarrhythmic drugs.
These ﬁndings may help clinicians in the selection of the treatment
modality.
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